Hemopoietic Growth and Inhibitory Factors in Treatment of Malignancies: A review

References

• Frei E, III, Antman K, Teicher B, et al. Bone marrow autotransplantation for solid tumors—Prospects. J Clin Oncol 1989; 7: 515–26
   PubMed Web of Science ®Google Scholar
• Cheson B D, Lacerna L, Leyland-Jones B, et al. Autologous bone marrow transplantation. Ann Intern Med 1989; 110: 51–65
   PubMed Web of Science ®Google Scholar
• Armitage J O, Gale R P. Bone marrow autotransplantation. Am J Med 1989; 86: 203–6
   PubMed Web of Science ®Google Scholar
• Bregni M, Siena S, Ravagnani F, et al. High-dose cyclophosphamide in patients with operable breast cancer: Recombinant human GM-CSF ameliorates drug-induced leukopenia and thrombocytopenia. J Clin Oncol 1991; 7: 159–67
   Google Scholar
• Groopman J E, Mitsuyasu R T, Deleo M J, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 1987; 317: 589–93
   Web of Science ®Google Scholar
• Bronchud M H, Scarf J H, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemo-therapy for small cell lung cancer. Br J Cancer 1987; 56: 809–13
   PubMed Web of Science ®Google Scholar
• Vadham-Raj S, Keating J, LeMaistre A, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 1987; 317: 1547–52
   Web of Science ®Google Scholar
• Gabrilove J L, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitionalcell carcinoma of the urothellum. N Engl J Med 1988; 318: 1414–22
   PubMed Web of Science ®Google Scholar
• Brandt B J, Peters W P, Atwater S K, et al. Effect of recombinant human granulocyte-macrophage colony stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318: 869–76
   PubMed Web of Science ®Google Scholar
• Antman K S, Griffin J D, Elians A, et al. Effect of recombinant human granulocyte-macrophage colony stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988; 319: 593–8
   PubMed Web of Science ®Google Scholar
• Bronchu M H, Howell A, Crowther D, et al. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 1989; 60: 121–5
   PubMed Web of Science ®Google Scholar
• Lieschke G J, Maher D, Cebon J, et al. Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. Ann Intern Med 1989; 110: 357–64
   PubMed Web of Science ®Google Scholar
• Graber S E, Krantz S B. Erythropoietin. Biology and clinical use. Hematol Oncol Clin North Am 1989; 3: 369–400
   PubMed Web of Science ®Google Scholar
• Cannistra S A, Griffin J D. Regulation of the production and function of granulocytes and monocytes. Semin Hematol 1988; 25: 173–88
   PubMed Web of Science ®Google Scholar
• Peters W P, Stuart A, Affronti M L, et al. Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans. Blood 1988; 72: 1310–5
   PubMed Web of Science ®Google Scholar
• Devereux S, Linch D C, Addison I E, et al. The effects of rhGM-CSF on circulating phagocytes in man. Blood 1987; 70: 133
   Google Scholar
• Ho A D, Del-Valle F, Engelhard M, et al. Mitoxant/high dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma. A pilot study. Cancer 1990; 66: 423–30
   PubMed Web of Science ®Google Scholar
• Bridell R A, Bruno E, Cooper R J, et al. Effect of c-kit ligand on in vitro human megakaryocytopoiesis. Blood 1991; 78: 2854–9
   PubMed Web of Science ®Google Scholar
• Siena S, Bregni M, Bonsi L, et al. Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors. Exp Hematol 1993; 21: 1583–90
   PubMed Web of Science ®Google Scholar
• Demetri G D, Spriggs D R, Sherman M L, et al. A phase I trial of recombinant human tumor necrosis factor and interferon-gamma. Effects of combination cytokine administration in vivo. J Clin Oncol 1989; 7: 1545–53
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Lotze M T, Muul L M, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889–905
   PubMed Web of Science ®Google Scholar
• Cannistra S A, Rambaldi A, Spriggs D R, et al. Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. J Clin Invest 1987; 79: 1720–8
   PubMed Web of Science ®Google Scholar
• Gianni A M, Bregni M, Siena S, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990; 8: 768–78
   PubMed Web of Science ®Google Scholar
• Morstyn G, Leischke G J, Sheridan W, Layton J, Cebon J, Fox R M. Clinical experience with recombinant human granulocyte colony-stimulating factor and granulocyte macro-phage colony-stimulating factor. Semin Hematol 1989; 26: 9–13
   PubMed Web of Science ®Google Scholar
• Frei E, III, Canellos G P. Dose: a critical factor in cancer chemotherapy. Am J Med 1980; 69: 585–94
   PubMed Web of Science ®Google Scholar
• Ferguson J E, Dodwell D J. High-dose dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer. Br J Cancer 1993; 67: 825–9
   PubMed Web of Science ®Google Scholar
• Focan C, Andrien J M, Closon M TH, et al. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial. J Clin Oncol 1993; 11: 1253–63
   PubMed Web of Science ®Google Scholar
• Hryniuk W M, Levine M N, Levin L. Analysis of dose-intensity for chemotherapy in early (stage II) and advanced breast cancer. NCI Monogr 1986; 1: 87–94
   PubMedGoogle Scholar
• Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1282–8
   Web of Science ®Google Scholar
• Metcalf D. The molecular control of blood cells. Harvard University Press, London 1988
   Google Scholar
• Smith J W, Urba W J, Curti B D, et al. The toxic and hematologic effects of interleukin-l alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992; 1141–52
   PubMed Web of Science ®Google Scholar
• Sanda M G, Yang J C, Topalian S L, et al. Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study. J Clin Oncol 1992; 10: 1643–9
   PubMed Web of Science ®Google Scholar
• Lord B I. Myeloid cell kinetics in response to hemopoietic growth factors. Bailliere's Clin Hematol 1992; 5: 533–50
   PubMedGoogle Scholar
• Sheridan W P, Morstyn G, Wolf M, et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; 2: 891–5
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Singer J W, Buckner C D, et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. Blood 1990; 76: 245–53
   PubMed Web of Science ®Google Scholar
• Nemunitis J, Rabinowe S N, Singer J W, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773–8
   PubMed Web of Science ®Google Scholar
• Ganser A, Lindemann A, Seipelf G, et al. Effect of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 1990; 76: 666–76
   PubMed Web of Science ®Google Scholar
• Brugger W, Frisch J, Schulz G, et al. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide and cisplatin. J Clin Oncol 1992; 10: 1452–9
   PubMed Web of Science ®Google Scholar
• Vredenburgh J, Ross M, Meisenberg B, et al. Use of interleukin-3 (IL-3) and/or GM-CSF in patients with metastatic breast cancer receiving high-dose chemotherapy (HDC) and immunopharmacologically purged (IMPP) autologous bone marrow support (P-AMBS) (Abstract 3). Proceedings of the 24th Congress of the International Society of Hematology, London, 1992
   Google Scholar
• Morstyn G, Stuart-Harris R, Bishop J, et al. Optimal scheduling of granulocyte-macrophage colony stimulating factor for the abrogation of chemotherapy induced neutropenia in small cell lung function. Proc Am Soc Clin Oncol 1989; 8: 218
   Google Scholar
• Herrmann F, Schulz G, Lindemann A, et al. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1989; 7: 159–67
   PubMed Web of Science ®Google Scholar
• Steward W P, Scarffe J H, Bonnem E, Crowther D. Clinical studies with recombinant human granulocyte-macrophage colony-stimulating factor. Int J Cell Cloning 1990; 8: 335–46
   PubMedGoogle Scholar
• Steward W P, Scarffe J H, Dirix L Y, et al. Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer. Br J Cancer 1990; 61: 749–54
   PubMed Web of Science ®Google Scholar
• Edmonson J H, Long H J, Jeffers J A, Buckner J C, Colon-Otero G, Fitch T R. Amelioration of chemotherapy-induced thrombocytopenia by GM-CSF: apparent dose and schedule dependency. J Natl Cancer Inst 1989; 81: 1510–1
   PubMed Web of Science ®Google Scholar
• Aglietta M, Piacibello W, Sanavio F, et al. Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. Am Soc Clin Invest 1989; 83: 551–7
   PubMed Web of Science ®Google Scholar
• Aglietta M, Piacibello W, Sanavio F, et al. Kinetics of human hemopoietic cells following in vivo administration of GM-CSF (abstr.). J Cell Biochem 1989; 48((Suppl. 13C))
   Google Scholar
• Vadhan-Raj S, Broxmeyer H, Hittleman W, et al. Two possible mechanisms for the abrogation of chemotherapy (CT) induced myelosuppression by GM-CSF: Increased myeloid mass and non-cycling progenitors (abstr.). Blood 1990; 76((Suppl.))
   Google Scholar
• Henderson I C, Hayes D F, Gelman R. Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 1988; 6: 1501–15
   PubMed Web of Science ®Google Scholar
• Klingemann H G. Clinical applications of recombinant human colony-stimulating factors. Can Med Assoc J 1989; 140: 137–42
   PubMed Web of Science ®Google Scholar
• Armitage J O, Jagannath S, Spritzer G, et al. High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma. Eur J Cancer Clin Oncol 1986; 22: 871–7
   PubMedGoogle Scholar
• Nemunaitis J, Singer J W, Buckner C D, et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies. Blood 1988; 72: 834–6
   PubMed Web of Science ®Google Scholar
• Devereux S, Linch D C, Gribben J G, McMillan A, Patterson K, Goldstone A H. GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease. Bone Marrow Transplant 1989; 4: 49–54
   Web of Science ®Google Scholar
• Devereux S, Goldstone A H, Patterson K, Linch D C. The use recombinant human granulocyte-macrophage colony-stimulating factor to accelerate recovery of the autologous bone marrow transplantation in man. Br J Hematol 1988; 69: 103
   PubMed Web of Science ®Google Scholar
• Bennett C L, Greenberg P, Gulati S C, Advani R, Bonnem E. GM-CSF decreases duration of cytopenia and hospitalization, and inhospital costs in patients with Hodgkin's disease treated with high-dose chemotherapy and autologous bone marrow transfusion (ABMT) (Abstr.). Blood 1990; 76((Suppl.))
   PubMedGoogle Scholar
• DeWitte T, Van Der Gratwohl, Lely N, et al. A multicentre double blind randomized trial of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in recipients of allogeneic T-cell depleted bone marrow (Abstr.). Blood 1990; 76((Suppl.))
   Google Scholar
• Link H, Boogaerts M, Carella A, et al. Recombinant human granulocyte-macrophage colony stimulating factor (rh-GM-CSF) after autologous bone marrow transplantation for acute lymphoblastic leukemia and non-Hodgkin's lymphoma: A randomized double blind multicentre trial in Europe (Abstr.). Blood 1990; 76((Suppl.))
   Google Scholar
• Rabinowe S, Freedman A, Demetri G, et al. Randomized double blinded trial of rhGM-CSF in patients with B-cell non-Hodgkin's lymphoma (B-NHL) undergoing high dose chemoradiotherapy and monoclonal antibody purged autologous bone marrow transplantation (ABMT) (Abstr.). Blood 1990; 76((Suppl.))
   Google Scholar
• Advani R, Greenberg P, Gulati S, Hoglund M, Bonnem E M. Randomized placebo controlled trial of granulocyte-macrophage colony stimulation factor in patients undergoing autologous bone marrow transplantation (BMT) (Abstr.). Blood 1990; 76((Suppl.))
   Google Scholar
• Gorin N C, Coiffier B, Pico J, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) shortens aplasia duration after autologous bone marrow transplantation (ABMT) in non-Hodgkin's lymphoma: a randomized placebo-controlled double-blind study (Abstr.). Blood 1990; 76((Suppl.))
   Google Scholar
• Singer J W, Nemunaitis J, Bianco J C, et al. rhGM-CSF following allogeneic bone marrow transplantation from unrelated marrow donors: A phase II study (Abstr.). Blood 1990; 76((Suppl.))
   PubMedGoogle Scholar
• Gadish M, Kletter Y, Flidel O, Nagler A, Slavin S, Fabian I. Effects of recombinant human granulocyte (G-CSF) and granulocyte/macrophage colony stimulating factor (GM-CSF) on neutrophil (PMN) function following autologous bone marrow transplantation (ABMT) (Abstr.). Blood 1990; 76((Suppl.))
   Google Scholar
• Hoelzer D F. Therapy of the newly diagnosed adult with acute lymphoblastic leukemia. Hematol Oncol Clin North Am 1993; 7: 139–60
   PubMed Web of Science ®Google Scholar
• Kessinger A. Reestablishing hematopoiesis after dose-intensive therapy with peripheral stem cells. High-dose cancer-therapy pharmacology, hematopoietins, stem cells, J O Armitage, K H Antman. Williams and Wilkins, Baltimore 1992; 182–94
   Google Scholar
• Kessinger A, Armitage J O. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 1991; 77: 211–3
   PubMed Web of Science ®Google Scholar
• Haas R, Hohaus S, Ehrhardt R, et al. Autologous blood prognitor celle transplantation in relapsed Hodgkin's disease—the role of hematopoietic growth factors. Bone Marrow Transplant 1993; 11((Suppl 2))30–5
   PubMedGoogle Scholar
• Sheridan W P, Begly C G, Juttner C A, et al. Effect of peripheral-blood prognitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640–4
   PubMed Web of Science ®Google Scholar
• Gianni A M, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating hemopoietic stem cells for auto-transplantation. Lancet 1989; 2: 580–5
   PubMed Web of Science ®Google Scholar
• Mazanet R, Elias A, Hunt M, et al. Peripheral blood prognitor cells (PBPC)s added to bone marrow (BM) for hemopoietic rescue following high dose chemotherapy for solid tumors reduces morbidity and length of hospitalisation (Abstract 1149). Proc Am Soc Clin Oncol 1991; 10: 324
   Google Scholar
• Grigg A. Effect of peripheral-blood progenitor cells mobilized by filgrastim (G-CSF) in platelet recovery after high-dose chemotherapy. Bone Marrow Transplant 1993; 11((Suppl. 2))23–9
   PubMedGoogle Scholar
• Long G, Chao N, Negrin R, et al. Efficacy of peripheral blood-derived stem cell (PBSC) rescue compared with bone marrow (BM) plus PBSC rescue after high-dose therapy. (Abstract 2190). Blood 1990; 76((Suppl 1))550a
   Google Scholar
• Fukada M, Kojima S, Matsumoto K, Matsuyama T. Autoransplantation of peripheral blood stem cells mobilized by chemotherapy and recombinant human granulocyte colony-stimulating factor in childhood neuroblastoma non-Hodgkin's lymphoma. Br J Hematol 1992; 80: 327–331
   PubMed Web of Science ®Google Scholar
• Pettengell R, Morgenstern G R, Wall P J, et al. Peripheral blood prognitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 1993; 82: 3770–7
   PubMed Web of Science ®Google Scholar
• Brugger W, Bross K J, Glatt M, et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636–40
   PubMed Web of Science ®Google Scholar
• Williams D A. Ex vivo expansion of hematopoietic stem and progenitor cells—robbing Peter to pay Paul? Blood 1993; 81: 3169–72
   Google Scholar
• Muench M O, Firpo M T, Moore M AS. Bone marrow transplantation with interleukin-1 plus kit—ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential. Blood 1993; 81: 3463–73
   PubMed Web of Science ®Google Scholar
• Brugger W, Moecklin W, Heinfeld S, et al. Ex vivo expansion of enriched peripheral blood CD 34+ progenitor cells by stem cell factor, IL-1β, IL-3 interferon γ and erythropoietin. Blood 1993; 81: 2579–84
   PubMed Web of Science ®Google Scholar
• VanHoef M EHM, Bauman I, Lange C, et al. Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Ann Oncol 1994; 5: 271–24
   Google Scholar
• Ganser A, Völkers B, Greher J, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with meylodysplastic syndromes—a phase I/II trial. Blood 1989; 73: 31–7
   PubMed Web of Science ®Google Scholar
• Thompson J A, Lee D J, Kidd P, et al. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with-myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J Clin Oncol 1989; 7: 629–37
   PubMed Web of Science ®Google Scholar
• Ganser A, Ottmann O G, Schultz G, Hoelzer D. Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine arabinoside in patients with myelodysplastic syndrome. Onkologie 1989; 12: 13–5
   PubMed Web of Science ®Google Scholar
• Schuster M W, Larson R A, Thompson J A, Coiffier B, Bennett J M, Israel R J. Granulocyte-macrophage colony-stimulating factor (GM-CSF) for myelodysplastic syndrome (MDS): results of a multi-centre randomized controlled trial (Abstr.). Blood 1990; 76((Suppl.))
   Google Scholar
• Willemz R, Visani G, De Witte T, et al. A randomized phase I/II study with recombinant human GM-CSF in patients (PTS) with myelodysplastic syndromes at a relatively low risk of developing acute leukemia (Abstr.). Blood 1990; 76((Suppl.))
   Google Scholar
• Gerhartz H H, Marcus R, Delmer A, et al. Randomized phase II study with GM-CSF and low-dose ARA-C in patients with ‘high risk’ myelodysplastic syndromes (MDS) (Abstr.). Blood 1990; 76((Suppl.))
   PubMedGoogle Scholar
• Bower R, Kelsey S M, Newland A C, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and vitamin D have an additive effect in cytopenic, symptomatic myelodysplasia (MDS) (Abstr. P 72). Br J Hematol 1994; 86((Suppl 1))51
   Google Scholar
• McCulloch E A, Minden M D, Miyauchi J, et al. Stem cell renewal and differentiation in acute myeloblastic leukemia. J Cell Sci 1988, (Suppl. 10): 267–81
   Google Scholar
• Nørgaard J M, Langkjer S T, Ellegaard J, Palshof T, Clausen N, Hokland P. Synergistic and antagonistic effects of myeloid growth factors on in vitro leukemia. Res 1993; 17: 689–94
   Google Scholar
• DeWitte T, Muus P, Haanen C, et al. GM-CSF enhances sensitivity of leukemic clonogenic cells to long-term dose cytosine arabinoside with sparing of the normal clonogenic cells. Behring Inst Mitt 1988; 83: 301–7
   Google Scholar
• Mazumder A, Agah R, Charak B. Novel use of GM-CSF as an anti-tumor immune potentiator after tansplantation (Abstr.). Blood 1990; 76((Suppl.))
   PubMedGoogle Scholar
• Ruff M R, Farrar W L, Pert C B. Interferon alpha and granulocyte/macrophage colony-stimulating factor inhibit growth and induce antigens characteristic of myeloid differentiation in small-cell lung cancer cell lines. Proc Natl Acad Sci USA 1986; 83: 6613–7
   PubMed Web of Science ®Google Scholar
• Hill A DK, et al. Antineoplastic effects of granulocyte macrophage-colony stimulating factor. Br J Surg 1992; 79: 459
   Google Scholar
• Baldwin G C, Dipersio J, Kaufmann S E, et al. Characterization of human GM-CSF receptors on non-hematopoietic cells. Blood 1987; 70: 166–72
   Google Scholar
• Munker M, Munker R, Saxton R E, Koeffier H P. Effect of recombinant monokines, lymphokines, and other agents on clonal proliferation of human lung cancer cell lines. Cancer Res 1987; 47: 4081–5
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Ziberia C, Gibelli N, Vacciocchi G, Robustelli Della, Cuna G, Cazzola M. GM-CSF and IL-3 stimulate proliferation of small-cell lung cancer (SCLC) cells (Abstr.). Blood 1990; 76((Suppl.))
   Google Scholar
• Baldwin G C, Golde D W, Economou J, Gasson J C. Identification and characterization of low affinity GM-CSF receptor on fresh and cultured human melanoma cells (Abstr.). Blood 1990; 76((Suppl.))
   PubMedGoogle Scholar
• Morstyn G, Burgess A W. Hemopoietic growth factors: a review. Cancer Res 1988; 48: 5624–37
   PubMed Web of Science ®Google Scholar
• Metcalf D. The colony stimulating factors. Discovery, development, and clinical applications. Cancer 1990; 65: 2185–95
   PubMed Web of Science ®Google Scholar
• Maekawa T, Metcalf D, Gearing D P. Enhanced suppression of human myeloid leukemic cell lines by combinations of IL-6, LIF, GM-CSF and G-CSF. Int J Cancer 1990; 45: 353–8
   PubMed Web of Science ®Google Scholar
• Gough N M, Williams R L, Hilton P J, et al. LIF: A molecule with divergent actions on myeloid leukemic cells and embryonic stem cells. Reprod Fertil Dev 1989; 1: 281–8
   PubMed Web of Science ®Google Scholar
• Gerhartz H H, et al. Randomized double-blind placebo controlled phase III study of recombinant human granulocyte/macrophage colony-stimulating factor (rhGM-CSF) as adjunet to induction-treatment of aggressive non-Hodgkin lymphomas. Blood 1993; 82: 2329–39
   PubMed Web of Science ®Google Scholar
• Edmonson J H, Long H L, Kvols L K. Cytotoxic drugs plus subcutaneous granulocyte/macrophage colony-stimulating factor: Can molgramostim enhance antisarcoma therapy?. J Natl Cancer Inst. 1994; 86, February 16
   PubMedGoogle Scholar
• Edmonson J H, Hartmann L C, Long H J, et al. Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influence of dose, schedule and route of administration in patients receiving cyclophasmide and carboplatin. Cancer 1992; 70: 2529–39
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, Lazarby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539–43
   PubMed Web of Science ®Google Scholar
• Golumbeck P T, Azhari R, Jaffee E M, et al. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res 1993; 53: 5841–4
   PubMed Web of Science ®Google Scholar
• Handman E, Burgess A W. Stimulation by granulocyte-macrophage colony-stimulating factor of Leishmania tropica killing by macrophages. J Immunol 1979; 122: 1134–7
   PubMed Web of Science ®Google Scholar
• Reed S G, Nathan C F, Pihl D L, et al. Recombinant human granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit trypanosoma cruzi and release hydrogen peroxide. J Exp Med 1987; 166: 1734–46
   PubMed Web of Science ®Google Scholar
• Cheers C, Haigh A M, Kelso A, Metcalf D, Stanley E R, Young A M. Production of colony-stimulating factors (CSFs) during infection: separate determinations of macrophage-, granulocyte-, granulocyte-macrophage- and multi-CSFs. Infect Immun 1988; 56: 247–51
   PubMed Web of Science ®Google Scholar
• Cebon J, Layton J E, Maker D, Morstyn G. Endogenous hemopoietic growth factors in neutropenia and infection. Br J Hematol 1994; 86: 265–74
   PubMed Web of Science ®Google Scholar
• Jensen W A, Rose R M, Burke R H, Jr, Anton K, Remold H G. Cytokine activation of antibacterial activity. Cell Immunol 1988; 117: 369–77
   PubMedGoogle Scholar
• Matsumoto M, Matsubara S, Yokota T. Effect of combination chemotherapy with recombinant human granulocyte colony-stimulating factor (γG-CSF) and antibiotics in neutropenic mice unresponsive to antibiotic alone. J Antimicrob Chemother 1991; 28: 447–93
   PubMed Web of Science ®Google Scholar
• Anaisse E, Bodey G P, Obrien S, Gutterman J, Vadhan-Raj S. Effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on myelopoiesis and disseminated mycoses in neutropenic patients with hematologic malignancies (Abstr.). 31st Annual Meeting of the American Society of Hematology. Blood 1989; 74((Suppl. 1))152
   PubMedGoogle Scholar
• Smith P D, Lamerson C L, Banks S M, et al. Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for candida albicans. J Infect Dis 1990; 161: 999–1005
   PubMed Web of Science ®Google Scholar
• Bodye G P, Anaisse E, Gutterman J, Vadhan-Raj S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993; 17: 705–7
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Swan F, Hagemeister F, et al. High dose ESHAP with GMCSF vs prophylactic antibiotics (Abstr.). Blood 1990; 76((Suppl.))
   Google Scholar
• Heyworth C M, Ponting I LO, Dexter T M. The response of hemopoietic cells to growth factors: developmental implications of synergistic interactions. J Cell Sci 1988; 91: 239–47
   PubMed Web of Science ®Google Scholar
• Dexter T M. Hemopoietic growth factors. Br Med Bull 1989; 45: 337–49
   PubMedGoogle Scholar
• Neidhart J, Mangalik A, Kohler W, et al. Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation. J Clin Oncol 1989; 7: 1685–92
   PubMed Web of Science ®Google Scholar
• Lord B I, Bronchud M H, Ownes S, et al. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci USA 1989; 86: 9499–503
   PubMed Web of Science ®Google Scholar
• Coutinho L H, Will A, Radford J, et al. Effects of recombinant human granulocyte colonyz-stimulating factor (CSF), human granulocyte macrophage-CSF, and gibbon interleukin-3 on hematopoiesis in human long-term bone marrow culture. Blood 1990; 75: 2118–29
   PubMed Web of Science ®Google Scholar
• Molineux G, Pojda Z, Dexter T M. A comparison of hematopoiesis in normal and splenectomized mice treated with granulocyte colony-stimulating factor. Blood 1990; 75: 563–9
   PubMed Web of Science ®Google Scholar
• Pojda Z, Molineux G, Dexter T M. Hemopoietic effects of short-term in vivo treatment of mice with various doses of rhG-CSF. Exp Hematol 1990; 18: 27–31
   PubMed Web of Science ®Google Scholar
• Pojda Z, Molineux G, Dexter T M. Effects of long-term in vivo treatment of mice with purified murine recombinant GM-CSF. Exp Hematol 1989; 17: 1100–4
   PubMed Web of Science ®Google Scholar
• Land R A, Metcalf D, Cuthbertson R A, et al. Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blondness, and a fatal syndrome of tissue damage. Cell 1987; 51: 675–86
   PubMed Web of Science ®Google Scholar
• Chang J M, Metcalf D, Gonda T J, Johnson G R. Long-term exposure to retrovirally expressed granulocyte-colony-stimulating factor induces a non-neoplastic granulocyte and progenitor cell hyperplasia without tissue damage in mice. Clin Invest 1989; 84: 1488–96
   Google Scholar
• Park L S, Gillis S, Urdal D L. Colony-stimulating factors, T M Dexter, J M Garland, N G Testa. Marcel Dekker Inc, New York 1990; 39
   Google Scholar
• Steward W P, Scarffe J H, Austin R, et al. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions—a phase I dose-toxicity study. Br J Cancer 1989; 59: 142–5
   PubMed Web of Science ®Google Scholar
• Berdel W E, Danhauser-Reidel S, Steinhauser G, Winton E F. Various human hematopoietic growth factors (Interleukin-3, GM-CSF, G-CSF) stimulate clonal growth of nonhematopoietic tumor cells. Blood 1989; 73: 80–3
   PubMed Web of Science ®Google Scholar
• Dedhar S, Gabory L, Galloway P, Eaves C. Human GM-CSF is a growth factor active on a variety of cell types of non-hematopoietic origin. Proc Natl Acad Sci USA 1988; 85: 9253
   PubMed Web of Science ®Google Scholar
• Bussolino F, Wang J M, DiFilippi P, et al. Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature 1989; 337: 471–3
   PubMed Web of Science ®Google Scholar
• Baker W J, Hargis J B, Danesi R, LaRocca R V. Effect of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) on the proliferation of osteogenic sarcoma cells (Abstr.). Blood 1990; 76((Suppl.))
   Google Scholar
• Foulke R S, Marshall M H, Trotta P P, Von Hoff D D. In vitro assessment of the effects of granulocyte-macrophage colony-stimulating factor on primary human tumors and derived lines. Cancer Res 1990; 50: 6264–7
   PubMed Web of Science ®Google Scholar
• Zsebo K, Suggs S, Johnson M, et al. Biological characterization and cloning of the genes for rat and human stem cell factor (Abstract 689). Blood 1990; 76((Suppl. 1))175a
   Google Scholar
• Atkins H L, Zsebo K M, Lin N, . Identification of the human stem cell factor (hSCF) receptor as C-kit and characterization of its structure. Recombinant human stem cell factor (rhSCF) stimulates in vitro and in vivo hematopoiesis in baboons (Abstract 509), R G Andrews, S H Bartelmez, J Egrie, et al. Blood. 1990; 76: 130a, (Suppl. 1)
   Google Scholar
• Andrews R G, Bartelmez S H, Egrie J, et al. Recombinant human stem cell factor/RHSCF stimulates in vitro and in vivo hematopoiesis in baboons (Abstract 511). Blood 1990; 76((Suppl.))130a
   Google Scholar
• Warren M K, Ralph P. Macrophage growth factor CSF-1 stimulates human monocyte production of interferon, tumor necrosis factor and colony stimulating activity. J Immunol 1986; 137: 2281–5
   PubMed Web of Science ®Google Scholar
• Fleit H, Rabinovtct M. Interferon induction in marrow-derived macrophages: regulation by L-cell conditioned medium. J Cell Physiol 1981; 108: 347–52
   PubMed Web of Science ®Google Scholar
• Ralph P, Nakoinz I. Stimulation of macrophage tumoricidal activity by the growth and differentiation factor CSF-1. Cell Immunol 1987; 105: 270–9
   PubMed Web of Science ®Google Scholar
• Camistra S A, Vellenga E, Groshek P, et al. Human granulocyte-monocyte colony stimulating factor and interleukin-3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood 1988; 71: 672–6
   PubMed Web of Science ®Google Scholar
• Carow C E, Hangoc G, Broxmeyer H E. Effects of IL-4 in in vitro cell growth. Br J Hematol 1993; 84: 365–73
   PubMedGoogle Scholar
• Bertolini F, Corsini C, Lauri E, et al. IL-4 induced inhibitory activity on neoplastic cell growth. Exp Hematol 1993; 22: 1204–9
   Google Scholar
• Miller L C, Preste G. Safety and toxicity of IL-4 after chemotherapy. Blood 1994; 7: 121–8
   Google Scholar
• Hokland P, Mikkelsen P, Segel E. IL-6 might relieve long-standing thrombocytopenia in autotransplant AML patients. Br J Hematol 1994; 87: 876–7
   PubMed Web of Science ®Google Scholar
• Graham G J, Wright E G, Hewick R, et al. Identification and characterization of an inhibitor of hemopoietic stem cell proliferation. Nature 1990; 344: 442–4
   PubMed Web of Science ®Google Scholar
• Vadham-Raj S, Broxmeyer H, Burgess M, et al. Schedule-dependent reduction in cyadic chemotherapy (CT)-induced multilineage hematopoietic toxicity by PIXY 321 in patients with sarcoma (Abstract 1653). ASCO 1994; 13: 475
   Google Scholar
• Stahl C P, Zucker-Franklin D, Evatt B L, Winton E F. Effects of human interluekin-6 on megakaryoctye development and thrombocytopoiesis in primates. Blood 1991; 78: 1467–75
   PubMed Web of Science ®Google Scholar
• deSauvage F J, Hass P E, Spenser S D, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the e-mpl ligand. Nature 1994; 369: 533–8
   PubMed Web of Science ®Google Scholar
• Methia N, Louche F, Vainchenker E, Wending F. Ologodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megaryocytopoiesis. Blood 1993; 82: 1395–401
   PubMed Web of Science ®Google Scholar
• McDonald T P. Megakaryoctye biology and precursors, B L Evatt, R F Levine, N T Williams. Elsevier Northe Holland, New York 1981; 39
   Google Scholar
• King-Smith E A, Morlye A. Computer stimulation of granu-lopoiesis. Normal and inpaired granulopoiesis. Blood 1970; 36: 254–62
   PubMedGoogle Scholar
• Roberts A B, Sporn M B. Transforming growth factor β. Adv Cancer Res 1988; 51: 107–45
   PubMed Web of Science ®Google Scholar
• Hampson J, Ponting I LO, Cook N, et al. The effects of TGF beta on hemopoietic cells. Growth Factors 1989; 1: 193–202
   PubMed Web of Science ®Google Scholar
• Sing G K, Keller J R, Ellingsworth L R, Ruscetti F W. Transforming growth factor β selectively inhibits normal and leukemic human bone marrow cell growth in vitro. Blood 1988; 72: 1504–11
   PubMed Web of Science ®Google Scholar
• Ottman O G, Pelus L M. Differential proliferative effects of transforming growth factor-β on human hematopoietic progenitor cells. J Immunol 1988; 140: 2661–5
   PubMed Web of Science ®Google Scholar
• Keller J R, Ellingsworth L R, McNiece I K, et al. Transforming growth factor β directly regulates primitive murine hematopoietic cell proliferation. Blood 1990; 75: 596–602
   PubMed Web of Science ®Google Scholar
• Keller J R, Mantel C, Sing G K, et al. Transforming growth factor β1 selectively regulates early murine hematopoietic progenitors and inhibits the growth of IL-3-dependent myeloid leukemia cell lines. J Exp Med 1988; 168: 737–50
   PubMed Web of Science ®Google Scholar
• Lord B I, Mori K S, Wright E G, Lajtha L G. An inhibitor of stem cell proliferation in normal bone marrow. Br J Hematol 1976; 34: 441–5
   PubMed Web of Science ®Google Scholar
• Lord B I. Biological regulation of cell proliferation, R Baserga. Serona Symp Pubs, New York 1986; vol. 34: 167
   Google Scholar
• Frindel E, Guigon M. Inhibition of CFU entry into cycli by a bone marrow extract. Exp Hematol 1977; 5: 74–6
   PubMed Web of Science ®Google Scholar
• Ohta M, Greenberger J S, Anklesaria P, et al. Two forms of transforming growth factor-β distinguished by multipotential hematopoietic progenitor cells. Nature 1987; 329: 539–41
   PubMed Web of Science ®Google Scholar
• Guigon M. The inhibitors of hemopoiesis, A Najma. Inserm/Libbey Eurotext, London 1987; 241
   Google Scholar
• Keller J R, Sing G K, Ellingsworth L R, Ruscetti F W. Transforming growth factor β: Possible roles in the regulation of normal and leukemic hematopoietic cell growth. J Cell Biochem 1989; 39: 175–84
   PubMed Web of Science ®Google Scholar
• Eaves A C, Cashman J D, Gaboury L A, et al. Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. Proc Natl Acad Sci USA 1986; 83: 5306–10
   PubMed Web of Science ®Google Scholar